Takeda Oncology
Rashmi Choudhary is a highly experienced professional in the field of biochemistry and translational medicine, with a comprehensive background in cell therapies and immunology. Currently serving as a Translational Strategy Leader for Cell Therapies at Takeda Oncology, Rashmi has previously held positions as a Senior Scientist at both Takeda Pharmaceuticals America, Inc. and AgenTus Therapeutics, as well as Scientist roles focused on immunology at TCR2, Inc. Rashmi's academic foundation includes a PhD in Biochemistry obtained from Osmania University between 1999 and 2006, along with research experience as a faculty member and postdoctoral fellow at Johns Hopkins University.
This person is not in the org chart
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.